The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Kaburaki S, Okada N, Tanaka T, Kamio K, Tanaka Y, Terasaki Y, Kasahara K, Seike M

Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy.

The Journal of dermatological treatment 2024 Dec;35;2424338 — 2024 Dec — 2424338

Ahmed A, Khanna P, Al Omari O, Jani C, Patel D, Singh H, Schiffman R

Ixekizumab-induced Interstitial Lung Disease.

American journal of therapeutics 2023 Jul 07;; — 2023 Jul 07

Matsumoto Y, Abe N, Tobita R, Kawakami H, Nakayama H, Setoguchi Y, Tsuboi R, Okubo Y

The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis.

Clinical and experimental dermatology 2020 Oct;45;853-858 — 2020 Oct — 853-858